Tisotumab vedotin

Tisotumab vedotin (Tivdak, Genmab A/S) has 1 EU-approved indication in 1 tumour type.
Approved indications of Tisotumab vedotin
Biomarker requirementRegimenSettingConditions
Cervical cancer1
None
Monotherapy
2L
advanced
Disease progression on or after systemic therapy
Full text of section 4.1 (therapeutic indications)

Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).

Label history

4 changes to the Tivdak label since 2025, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes